Publications

February 2005
Article

Managing the Ecosystem

By: Marco Iansiti

The days of the corporate lone wolf are over. In our increasingly interconnected world, standing alone is no longer a viable business model. Instead, smart companies rely heavily on networks of partners, suppliers, and customers to achieve market success and sustain... View Details

Keywords: Integrated Corporate Reporting; Partners and Partnerships; Industry Clusters; Customers; Markets; Situation or Environment; Banks and Banking; Insurance; Software

Find at Harvard

11 Oct 2017
Working Paper Summaries

Crime and Violence: Desensitization in Victims to Watching Criminal Events

Keywords: by Rafael Di Tella, Lucia Freira, Ramiro H. Gálvez, Ernesto Schargrodsky, Diego Shalom, and Mariano Sigman

2009
Article

Synthesis by Microbes or Chemists? Pharmaceutical Research and Manufacturing in the Antibiotic Era

By: Arthur A. Daemmrich

This article presents a case study of the rise of Pfizer as a leading pharmaceutical company, with a focus on changing relationships between manufacturing technology and R&D between the mid-1940s and the mid-1960s. Pfizer first moved into pharmaceuticals through... View Details

Keywords: Research and Development; Production; Technology; Transformation; Relationships; Success; Organizations; Programs; Chemicals; Alignment; Pharmaceutical Industry; United States

Find at Harvard

12 Jul 2016
First Look

July 12, 2016

spending. Whereas traditional (small-molecule) drugs have historically faced price competition from generic drugs after patent expiration, biosimilars—biologic drugs that have been shown to be therapeutically equivalent to an already approved View Details

Keywords: Sean Silverthorne

15 Jul 2020
News

The Good Side of Bad Feelings

Article

Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users

By: Ariel Dora Stern, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup and Ernst R. Berndt

Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the U.S. and worldwide. Against this backdrop, many look to the expanding market for biosimilars—follow-on products to biologic drugs—as a vehicle for controlling... View Details

Keywords: Pharmaceuticals; Drug Spending; Drug Pricing; Health Care and Treatment; Spending; Price; Markets; Cost Management; United States

Research Summary

Risk, Trust and Escalation Behavior of Owner Managers

By: Cynthia A. Montgomery

Professor Montgomery and Professor Deepak Malhotra (HBS), together with scientists from Harvard's Program on Evolutionary Dynamics, are studying risk-related decision making of owner managers in newly-founded and established companies. This experimental... View Details

May 2016
Case

AbbVie

By: Kevin Schulman, Laura Little, Samyukta Mullangi and Stephen Schleicher

This case focuses on the impact of a novel regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging biosimilars... View Details

Keywords: Pharmaceutical Company; M＆A Valuation; AbbVie; Health Care; Health Care and Treatment; Pharmaceutical Industry; Health Industry; United States

14 Apr 2010
News

Straight Talk: Oprah's Leadership Lessons

15 Jun 2021
News

Podcast: How Biosimilars Are Affecting the Drug Markets

March 2018 (Revised March 2019)
Case

Gender and Free Speech at Google (A)

By: Nien-hê Hsieh, Martha J. Crawford and Sarah Mehta

In August 2017, Google fired James Damore, a 28-year-old software engineer who had been employed by the company since 2013. The move came after Damore penned an internal company memo titled “Google’s Ideological Echo Chamber,” which posited that innate biological... View Details

Keywords: Free Speech; Representation; Diversity; Gender; Race; Human Resources; Employees; Employee Relationship Management; Recruitment; Selection and Staffing; Labor; Employment; Lawsuits and Litigation; Organizational Culture; Technology Industry; United States; California

June 2016 (Revised August 2019)
Case

Numenta: Inventing and (or) Commercializing AI

By: David B. Yoffie, Liz Kind and David Ben Shimol

In March 2016, Donna Dubinsky (co-founder and CEO) and Jeff Hawkins (co-founder) were struggling with a key question: Could Numenta be successful in both creating fundamental technology and building a commercial business? Located in Redwood City, CA, Numenta was... View Details

Keywords: Artificial Intelligence; Machine Intelligence; Machine Learning; Strategy; Business Model; Entrepreneurship; Information; Technological Innovation; Research; Research and Development; Information Technology; Applications and Software; Technology Adoption; Digital Platforms; Commercialization; AI and Machine Learning

Research Summary

Understanding Human Nature

By: Nitin Nohria

Recent advances in biological sciences provide great insights into the workings of the human brain and thereby into human nature. Drawing upon this research, my colleague Paul Lawrence and I propose a neo-Darwinian theory of human motivation based on four basic human... View Details

07 Mar 2019
HBS Seminar

Petra Moser, NYU Stern School of Business

Article

Matriarch: A Python Library for Materials Architecture

By: Tristan Giesa, Ravi Jagadeesan, David I. Spivak and Markus J. Buehler

Biological materials, such as proteins, often have a hierarchical structure ranging from basic building blocks at the nanoscale (e.g., amino acids) to assembled structures at the macroscale (e.g., fibers). Current software for materials engineering allows the user to... View Details

Keywords: Building Block; Category Theory; Hierarchical Protein Materials; Molecular Design; Open-Source Software; Structure Creation

Find at Harvard

October 2022
Case

Afrigen Biologics: Vaccines for the Global South

By: Debora L. Spar and Julia Comeau

The majority of vaccines used on the continent of Africa (99%) are produced offshore. This makes African nations reliant on the West for major health care needs, a problem which was exacerbated by the COVID-19 pandemic. Afrigen Biologics (in partnership with the WHO)... View Details

Keywords: Vaccination; Vaccine; mRNA; COVID; COVID-19; Inequity; Hub-and-spoke; Health Care and Treatment; Health Pandemics; Production; Social Issues; Business and Government Relations; South Africa; Africa